Trials / Terminated
TerminatedNCT00427583
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | imatinib mesylate |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2009-04-01
- First posted
- 2007-01-29
- Last updated
- 2012-08-07
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00427583. Inclusion in this directory is not an endorsement.